Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.

ABSTRACT:

SUBMITTER: Zeidan AM 

PROVIDER: S-EPMC9305088 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature